Video

Review of Updated Efficacy and Safety Data from the EMPOWER-CSCC-1 Trial

Author(s):

Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Related Content
Melanoma | Maris– stock.adobe.com
April 25th 2025

China’s NMPA Approves Toripalimab in First-Line Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Uveal Melanoma | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 3rd 2025

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Neoadjuvant Pembrolizumab in Melanoma | Image Credit: © ReisMedia - stock.adobe.com
March 30th 2025

Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma

New Combination Therapy for Melanoma | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 28th 2025

New Drug Therapy Combination Shows Promise For Advanced Melanoma Patients